Hilary Tindle, MD, MPH, associate professor of medicine, at Vanderbilt University, discusses how the nicotine metabolite ratio (NMR) can help inform doctors and patients on choosing the optimal treatment for quitting smoking.
Although not a standard of care, the nicotine metabolite ratio (NMR) helps doctors and patients in a clinical care setting jointly make a decision on the best treatment approaches for quitting smoking for that individual, noted Hilary Tindle, MD, MPH, associate professor of medicine, at Vanderbilt University.
Transcript
How can the NMR best be implemented into clinical care for nicotine and smoking treatments?
The NMR, or nicotine metabolite ratio, is not currently standard of care. Right now, if a patient comes into the doctor's office and wants to quit smoking or is goaded into quitting smoking, guilted into it by the provider, is motivated to quit, we don't typically use the nicotine metabolite ratio. It's just a conversation with a patient, sometimes their family, about all the options. So, nicotine replacement, varenicline, bupropion is another prescription medicine that is FDA approved for quitting. And then based on that conversation, the patient and the health care provider jointly make a decision [on] what's the best medicine.
The nicotine metabolite ratio is a precision approach that could actually inform what's the best medicine. Is it going to be varenicline? The faster metabolizers, people whose livers break down nicotine faster, tend to do better with varenicline; they quit twice as often on varenicline, also called Chantix, compared to the nicotine patch. So that's just one way that precision medicine can actually be folded into the current process of clinical care. But it's not standard of care yet.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More